Company profile
Yarrow Bioscience, Inc.
NASDAQ:YARWBiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07682896 | phase2 | recruiting | 2026-06-10 | 2027-12-01 | Yarrow Bioscience, Inc. | Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease |
FDA applications (0)
No records yet.